Bicara Leads Trio of US Biotech IPOs Raising $703 Million [Yahoo! Finance]
MBX Biosciences, Inc. (MBX)
Company Research
Source: Yahoo! Finance
(Bloomberg) -- A trio of biotech companies sold shares in their initial public offerings on Thursday, an encouraging sign for a sector whose new entrants have lately struggled. Most Read from Bloomberg Bicara Therapeutics Inc. expanded its IPO to sell 17.5 million shares at $18 each, at the top of the price range, to raise $315 million, according to a statement. The company had boosted the number of shares on Wednesday, a regulatory filing showed. MBX Biosciences Inc. raised $163.2 million in its enlarged first-time share sale, pricing 10.2 million shares at $16 each, according to a statement. The number of shares was increased from 8.5 million and they priced at the top of a marketed range. Also on Thursday, Zenas BioPharma Inc. raised $224.4 million in its first-time sale that was upsized, according to a statement. The firm priced 13.2 million shares at $17 each, the middle of the marketed range. The IPOs are tasked with wiping the slate clean after a string of lackluster
Show less
Read more
Impact Snapshot
Event Time:
MBX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MBX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MBX alerts
High impacting MBX Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
MBX
News
- MBX Biosciences Announces Last Subject Last Visit in Phase 1 Trial of MBX 1416 for the Treatment of Post-Bariatric HypoglycemiaGlobeNewswire
- MBX Biosciences Reports Third Quarter 2024 Financial Results and Provides Business UpdateGlobeNewswire
- MBX Biosciences to Participate in Upcoming November Investor ConferencesGlobeNewswire
- MBX Biosciences, Inc. (NYSE: MBX) is now covered by analysts at Guggenheim. They set a "buy" rating and a $44.00 price target on the stock.MarketBeat
- MBX Biosciences, Inc. (NYSE: MBX) is now covered by analysts at JPMorgan Chase & Co.. They set an "overweight" rating and a $30.00 price target on the stock.MarketBeat
MBX
Sec Filings
- 11/8/24 - Form SC
- 11/7/24 - Form 10-Q
- 11/7/24 - Form 8-K
- MBX's page on the SEC website